Q2 Earnings Misses: UAA, DKNG, ASIX Disappoint — ANIP the Sole Beat

The Quick Take

• Under Armour (UAA) Q1 EPS of $0.00 missed estimates; $1.1B revenue reflects ongoing brand recovery struggles
• DraftKings (DKNG) Q2 EPS missed despite strong consumer volumes; heavy promotions weigh on net revenue
• AdvanSix (ASIX) Q2 EPS of $0.12 missed estimates amid persistent nylon intermediates margin pressure
• ANI Pharmaceuticals (ANIP) was the lone beat: Q2 EPS $1.05 on $266M revenue; 2026 guidance affirmed

Thursday's earnings session was broadly disappointing across apparel, gaming, and specialty chemicals. Under Armour delivered Q1 EPS of exactly $0.00, missing analyst expectations as the sportswear brand continues to navigate a difficult turnaround. Revenue came in near $1.1 billion, reflecting tepid North American demand amid shifting consumer preferences. The company's GF Score of 59 places it in the undervalued zone, but investors are growing impatient for tangible evidence that brand investment is converting to sustainable revenue growth.

DraftKings reported a Q2 earnings miss despite robust consumer handle volumes, underscoring the fundamental tension between growth and profitability in online sports betting. Heavy promotional spending to acquire and retain customers continues to erode net revenue margins. AdvanSix also missed Q2 estimates with EPS of $0.12, as nylon intermediates pricing remained under pressure from feedstock costs and competitive dynamics in the global specialty chemicals market. Both companies face multi-quarter recovery timelines before margins can normalize.

ANI Pharmaceuticals provided the session's sole bright spot, posting Q2 EPS of $1.05 on revenue of $266 million and reaffirming its 2026 full-year guidance. The specialty pharmaceutical company's solid execution in branded and generic drug segments contrasted sharply with the broader pattern of misses. Four misses against one beat signals that the Q2 2026 mid-cap earnings season remains challenging for consumer-facing and cyclical businesses, with investors focused on H2 2026 guidance clarity from these names.

Synthesized from 5 sources.